Articles tagged with: Pomalyst
This year’s American Society of Clinical Oncology (ASCO) annual meeting in Chicago ended last Tuesday.
The day before the meeting ended was the busiest day at the meeting with regard to myeloma research. It featured a session of oral presentations in the morning and a poster session in the afternoon. In addition, an education session was held in the afternoon that included one myeloma-related talk, given by Dr. Leif Bergsagel of the Mayo Clinic, about progress in the treatment of multiple myeloma (article in the ASCO 2014 Educational Book). …
The Beacon is pleased to introduce our newest myeloma thought leader columnist, Dr. Ravi Vij. Every three months, Dr. Vij will share with us a new edition of “The Myeloma Quiz,” which will test your knowledge and understanding of the myeloma-related research published during the previous several months.
We hope you will join us in welcoming Dr. Vij to the Beacon community, and in thanking him for sharing with us his valuable perspectives.
The relentless grind in the battle against myeloma continues. The last several months have seen some …
The year 2013 is likely to be remembered as a very good year when it comes to research related to multiple myeloma.
Previous years have witnessed research shedding new light on existing myeloma therapies, as well as additional research about potential new therapies.
But, in the past, most of the important new therapies that were being researched were from existing classes of therapy, making them less likely to offer dramatic improvements in the treatment of the disease.
In 2013, not only was there more research about existing therapies, and more …
Pomalyst is now approved in Canada for the treatment of certain patients with multiple myeloma.
Specifically, Health Canada approved Pomalyst (pomalidomide, Imnovid) for use in combination with dexamethasone (Decadron) in patients with multiple myeloma for whom both Revlimid (lenalidomide) and Velcade (bortezomib) have failed, who have received at least two prior treatment regimens, and who have demonstrated disease progression on their last therapy.
Health Canada approved Pomalyst on January 20, but the approval was first announced this morning.
Celgene (NASDAQ: CELG), the company that developed and markets Pomalyst, …
At the 2013 annual meeting of the American Society of Hematology (ASH), which took place in December, there were many oral and poster presentations about Pomalyst, the newest drug approved in the United States and Europe for the treatment of multiple myeloma.
Many of the presentations were about studies of Pomalyst (pomalidomide, Imnovid) and dexamethasone (Decadron) in combination with a third drug, such as Velcade (bortezomib), Kyprolis (carfilzomib), clarithromycin (Biaxin), cyclophosphamide (Cytoxan), or Doxil (doxorubicin liposomal), for relapsed and refractory myeloma. …